IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track

IDEAYA Biosciences, Inc.

2024-Q1 EPS reported -$0.53

Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.
Darovasertib neoadjuvant UM Phase 2 IST oral presentation at ASCO 2024; company-sponsored update on >30 patients and FDA guidance targeted H2 2024.
Selected Phase 2 dose for IDE397 in MTAP-deletion squamous NSCLC based on multiple PRs by RECIST 1.1; multiple PRs also in MTAP bladder cancer.
IND-enabling GLP tox completed for Werner Helicase inhibitor with GSK; IND filing targeted H2 2024 as 5th first-in-class clinical program.
Targeting FPI for IDE397+Trodelvy in MTAP bladder cancer mid-2024; Phase 2 expansion for IDE161 in HRD and combo with KEYTRUDA in endometrial cancer in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEAYA Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-053900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.